These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27465216)

  • 1. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
    Villalón CM; VanDenBrink AM
    Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Migraine: pathophysiology, pharmacology, treatment and future trends.
    Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
    Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
    Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
    Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the 5-HT
    Huang PC; Yang FC; Chang CM; Yang CP
    Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
    Gupta S; Villalón CM
    Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT
    Edvinsson JCA; Maddahi A; Christiansen IM; Reducha PV; Warfvinge K; Sheykhzade M; Edvinsson L; Haanes KA
    J Headache Pain; 2022 Feb; 23(1):26. PubMed ID: 35177004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Side effects associated with current and prospective antimigraine pharmacotherapies.
    González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present and future of 5-HT receptor agonists as antimigraine drugs.
    Pauwels PJ; John GW
    Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.
    Muñoz-Islas E; Lozano-Cuenca J; González-Hernández A; Ramírez-Rosas MB; Sánchez-López A; Centurión D; Maassenvandenbrink A; Villalón CM
    Eur J Pharmacol; 2009 Aug; 615(1-3):133-8. PubMed ID: 19460365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted 5-HT
    Vila-Pueyo M
    Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lasmiditan mechanism of action - review of a selective 5-HT
    Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
    J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
    Mitsikostas DD; Tfelt-Hansen P
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of the 5-HT1B/1D receptor agonists.
    Tepper SJ; Rapoport AM; Sheftell FD
    Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Journey of the Non-Vascular Relief for Migraine: From 'Triptans' To 'Ditans'.
    Xavier AS; Lakshmanan M; Gunaseelan V
    Curr Clin Pharmacol; 2017; 12(1):36-40. PubMed ID: 28425871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
    Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From serotonin receptor classification to the antimigraine drug sumatriptan.
    Saxena PR; Ferrari MD
    Cephalalgia; 1992 Aug; 12(4):187-96. PubMed ID: 1326401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
    Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
    Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CGRP and 5-HT
    Moreno-Ajona D; Chan C; Villar-Martínez MD; Goadsby PJ
    Headache; 2019 Jul; 59 Suppl 2():3-19. PubMed ID: 31291016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.